Current Controversies in Oncology

Current Controversies in Oncology and Current Insights in Oncology articles provide a forum for the exchange of views on topical issues in the field of oncology. The opinions expressed are those of the authors alone. They do not necessarily reflect the views of the Editor or ASCO.

Americans are not dying well. Jeanie M. Youngwerth, MD, and D. Ross Camidge, MD, PhD, discuss the use of cancer therapy in tandem with palliative care in this article, with an introduction by Daniel W. Bowles, MD.

Dr. Robert Rifkin and Dr. Huub Schellekens provide an excellent discussion of the opportunities presented by biosimilar agents and several of the misconceptions or myths that have arisen around their development and use in oncology practice.

There have been significant advances in the treatment of metastatic colorectal cancer. New chemotherapy has improved survival and response rates. Advances in surgical technique and expanded criteria for resectability of liver metastases have further improved survival rates.

Each year, over 1.6 million Americans and 14 million people worldwide are diagnosed with cancer. Further, cancer causes the deaths of 600,000 people annually in the United States and over eight million people globally. It is estimated that only 5% to 10%...

In this edition of Current Controversies in Oncology, expert hepatobiliary surgical oncologists debate the added benefit of neoadjuvant therapy for resectable hepatic colorectal metastases. While few would downplay the option of systemic therapy for a patient with bilobar metastases....

Jeff P. Sharman, MD, on why traditional chemoimmunotherapy with FCR should still be considered for ongoing use as an effective therapy: “If a fit younger patient has a favorable risk profile, intense chemoimmunotherapy may be the best route for long-term disease control—and possibly cure.”